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2015;8:e003744.Evaluating Statin Versus
Statin Plus Ezetimibe
for Coronary Plaque
RegressionTsujita et al. (1) reported the results of the PRECISE-
IVUS (Plaque Regression With Cholesterol Absorption
Inhibitor or Synthesis Inhibitor Evaluated by
Intravascular Ultrasound) trial which found that,
compared with standard statin monotherapy, the
combination of statin plus ezetimibe showed greater
coronary plaque regression in a secondary prevention
setting, and suggested that the clinical event risk
reduction in the IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efﬁcacy International Trial) (2)
might have been derived from the suppression effect
of coronary atherosclerotic development by dual
lipid lowering therapy. However, after 12 months of
follow-up in the PRECISE-IVUS trial (1) there have
been no differences in clinical events between the
two groups. Of note, in the similar population
enrolled in the IMPROVE-IT (2), with a follow-up
of 7 years, it has been shown that the truly
signiﬁcant event reductions, which led to the tiny
absolute beneﬁt in composite endpoint, of lowering
low-density lipoprotein cholesterol (LDL-C) with
ezetimibe added to simvastatin was driven by both
coronary revascularization (an endpoint notoriously
subject to preference that falsely inﬂates beneﬁts) (3)
and non-fatal myocardial infarction. Furthermore,
it was not mentioned how many myocardial
infarctions were procedure-related (2).
Indeed, loss of blinding to treatment allocation
might have probably occurred in the IMPROVE-IT (2)because dual lipid-lowering therapy predictably
greatly lowers LDL-C, and physicians who managed
the patients knew the lipid variables (4). Loss of
blinding might bias decisions about revascularization
procedures and, in the ezetimibe plus statin group,
loss of blinding could further result in fewer
myocardial infarctions secondary to these procedures
(5). The outcome least subject to bias is obviously
all-cause mortality. In the IMPROVE-IT, the striking
absence of beneﬁt in reducing deaths from any cause,
accompanied by the failure to reduce deaths from
cardiovascular cause and from coronary heart disease
in a high risk population, is worrying.
As practicing physicians, we would hesitate to
prescribe an expensive therapy which may lead, at
best, to few mm3 reduction in atheroma volume
without meaningful reductions in clinical events.*Luca Mascitelli, MD
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cet;380:18145.REPLY: Evaluating Statin Versus Statin Plus
Ezetimibe for Coronary Plaque RegressionWe have read with great interest the letter by Drs.
Mascitelli and Goldstein commenting on our recent
paper (1), in which we showed that the combination
of statin plus ezetimibe demonstrated greater
coronary plaque regression compared with statin
monotherapy. First of all, the PRECISE-IVUS (Plaque
Regression With Cholesterol Absorption Inhibitor
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statistically designed to evaluate the effect of the
dual lipid-lowering on “coronary plaque regression”
with the IVUS-derived percent atheroma volume as a
primary endpoint (2). Therefore, the PRECISE-IVUS
naturally lacked adequate statistical power to
detect the difference of cardiovascular event risk
reduction effect. However, a prior large meta-
analysis suggested a direct relationship between the
IVUS-derived measures of coronary atherosclerotic
plaque burden and adverse cardiovascular events,
supporting the use of atherosclerosis imaging with
IVUS in the evaluation of novel antiatherosclerotic
therapies (3). Consistent with the meta-analysis,
the antiatherosclerotic efﬁcacy of the combination
strategy shown by the PRECISE-IVUS seems to result
in the event risk reduction observed in IMPROVE-IT
(Improved Reduction of Outcomes: Vytorin Efﬁcacy
International Trial) (4). We thus believe that the
event risk reduction in the IMPROVE-IT was at
least partially derived from the suppression effect
of coronary atherosclerotic development by dual
lipid-lowering therapy.
Drs. Mascitelli and Goldstein are appropriately
concerned about: 1) the blinding to treatment alloca-
tion in the IMPROVE-IT; and 2) clinical signiﬁcance
and therapeutic cost of the dual lipid-lowering
pharmacotherapy. Regarding the blinding method of
the IMPROVE-IT, the monitoring of low-density lipo-
protein cholesterol and simvastatin uptitration were
strictly performed in a double-blind manner as shown
in the protocol paper (5). In terms of the clinical beneﬁt
of dual lipid-lowering evidenced by the PRECISE-IVUS
and the IMPROVE-IT, as the extremely lower rate
of hard endpoints (e.g., cardiovascular death)
achieved by the optimal medical therapy (e.g., dual
antiplatelet therapy, statins, and renin-angiotensin
system blockers) and coronary revascularization
in the current era makes it difﬁcult to detect the
risk reduction effect of a novel treatment in
cardiovascular mortality, the antiatherosclerotic
effect-derived reduction in risk of myocardial
infarction and coronary revascularization (even not
in cardiovascular death) would be considerably“meaningful” especially in the secondary prevention
setting.*Kenichi Tsujita, MD, PhD
Seigo Sugiyama, MD, PhD
Hideki Shimomura, MD, PhD
Kenshi Yamanaga, MD
Koichi Kaikita, MD, PhD
Seiji Hokimoto, MD, PhD
Hisao Ogawa, MD, PhD
for the PRECISE-IVUS Investigators
*Department of Cardiovascular Medicine
Graduate School of Medical Sciences
Kumamoto University, Honjo
1-1-1 Chuo-ku
Kumamoto 860-8556
Japan
E-mail: tsujita@kumamoto-u.ac.jp
http://dx.doi.org/10.1016/j.jacc.2015.09.098
Please note: Dr. Tsujita was supported in part by a Grant-in-Aid for Young
Scientists B (22790713, 24790769) and a Grant-in-Aid for Scientiﬁc Research C
(26461075) from the Ministry of Education, Science, and Culture, Japan.
Dr. Ogawa has received remuneration for lectures from Bayer, Boehringer
Ingelheim, Daiichi-Sankyo, MSD, Pﬁzer, and Takeda; has received trust
research/joint research funds from Bayer, Daiichi-Sankyo, and Novartis; and has
received scholarship funds from AstraZeneca, Astellas, Bristol-Myers Squibb,
Chugai, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Otsuka,
Pﬁzer, Sanoﬁ, Shionogi, and Takeda. All other authors have reported that they
have no relationships relevant to the contents of this paper to disclose.
REF ER ENCES
1. Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering
strategy with ezetimibe and atorvastatin on coronary plaque regression
in patients with percutaneous coronary intervention: the multicenter
randomized controlled PRECISE-IVUS Trial. J Am Coll Cardiol 2015;66:
495–507.
2. Tsujita K, Sugiyama S, Sumida H, et al. Plaque REgression with Cholesterol
absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular Ultra-
Sound (PRECISE-IVUS Trial): study protocol for a randomized controlled trial.
J Cardiol 2015;66:353–8.
3. Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasound-derived mea-
sures of coronary atherosclerotic plaque burden and clinical outcome. J Am
Coll Cardiol 2010;55:2399–407.
4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin
therapy after acute coronary syndromes. N Engl J Med 2015;372:
2387–97.
5. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of
IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efﬁcacy International
Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy
on cardiovascular outcomes in patients with acute coronary syndromes. Am
Heart J 2008;156:826–32.
